House FY24 spending bill slashes NIH by 6%, NCI by 3%

In The Headlines: Private funding can’t replace federal funding—but it can help

In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.

April 09, 2025

Vol.51 No.13

Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure

The day before health economist Jay Bhattacharya stepped into his new role as NIH director, he sent a document to his employees outlining his top five priorities for the department, which included “reproducibility” and “transparency,” two themes he discussed at his confirmation hearings (The Cancer Letter, March 7, 2025).

April 04, 2025

Vol.51 No.13

By Claire Marie Porter, Paul Goldberg and Jacquelyn Cobb

Guest Editorial

Rathmell: We must put the individual at the center of our approach to ending cancer

When I started this column, I was wanting to retain the sense of connection that I had to the greater cancer community as I stepped away into a period of disconnection.

April 04, 2025

Vol.51 No.13

By W. Kimryn Rathmell

In the Archives

In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously

Credit: NCI/Linda BartlettIn an oral history conducted by FDA in September 2013, Andrew C. von Eschenbach recounted his eight-month stint in a dual role as both FDA acting commissioner and NCI director.

Fatty acids promote immune suppression and therapy resistance in triple negative breast cancer, Baylor Medicine study finds

A study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.

April 04, 2025

Vol.51 No.13

Podcast

In The Headlines: HHS shakeup threatens a legacy of medical breakthroughs

“For the last 50 years every major medical breakthrough can be traced back to investments in the NIH, which houses the National Cancer Institute (NCI),” said Wayne A. I. Frederick, interim chief executive officer of American Cancer Society and the American Cancer Society Cancer Action Network.

April 02, 2025

Vol.51 No.12

House FY24 spending bill slashes NIH by 6%, NCI by 3%

YOU MAY BE INTERESTED IN

In The Headlines: Private funding can’t replace federal funding—but it can help

Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure

Rathmell: We must put the individual at the center of our approach to ending cancer

In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously

Fatty acids promote immune suppression and therapy resistance in triple negative breast cancer, Baylor Medicine study finds

In The Headlines: HHS shakeup threatens a legacy of medical breakthroughs

Renew today!

Subscriber content

House FY24 spending bill slashes NIH by 6%, NCI by 3%

YOU MAY BE INTERESTED IN

In The Headlines: Private funding can’t replace federal funding—but it can help

Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDAMeanwhile, NASEM sounds “SOS” for health infrastructure

Rathmell: We must put the individual at the center of our approach to ending cancer

In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously

Fatty acids promote immune suppression and therapy resistance in triple negative breast cancer, Baylor Medicine study finds

In The Headlines: HHS shakeup threatens a legacy of medical breakthroughs

Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure